PFIZER INC

NYSE: PFE (Pfizer, Inc.)

Last update: 13 hours ago

30.77

1.01 (3.39%)

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish -
Drug Manufacturers - General (Global) Bullish -
Stock Pfizer, Inc. Bullish -

Stockmoo Score

1.5

Similar Stocks

Stock Market Cap DY P/E P/B
PFE 174 B 5.40% - 1.89
JNJ 387 B 2.99% 24.30 5.40
ABBV 285 B 3.76% 48.13 38.86
BMY 84 B 5.63% - 5.56
LLY 823 B 0.53% 135.09 60.43
MRK 320 B 2.40% 140.50 7.90

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
52 Weeks Range
25.20 (-18%) — 37.19 (20%)
Price Target Range
29.00 (-5%) — 45.00 (46%)
High 45.00 (Cantor Fitzgerald, 46.25%) Buy
Median 33.00 (7.25%)
Low 29.00 (Morgan Stanley, -5.75%) Hold
Average 35.00 (13.75%)
Total 2 Buy, 2 Hold
Avg. Price @ Call 28.03
Firm Date Target Price Call Price @ Call
Barclays 10 Jul 2024 30.00 (-2.50%) Hold 28.35
Cantor Fitzgerald 10 Jul 2024 45.00 (46.25%) Buy 28.35
01 Jul 2024 45.00 (46.25%) Buy 28.22
BMO Capital 02 May 2024 36.00 (17.00%) Buy 27.70
Morgan Stanley 02 May 2024 29.00 (-5.75%) Hold 27.70

No data within this time range.

  • 3M
Date Type Details
25 Jul 2024 Announcement European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
24 Jul 2024 CNBC Pfizer's gene therapy for rare genetic bleeding disorder succeeds in late-stage trial
24 Jul 2024 Announcement Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
23 Jul 2024 Announcement ViiV Healthcare announces positive data demonstrating 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy for maintenance therapy of HIV-1
17 Jul 2024 Announcement CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts
11 Jul 2024 Announcement Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
11 Jul 2024 CNBC Pfizer moves forward with once-daily version of weight loss pill after setbacks
09 Jul 2024 Announcement Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development
08 Jul 2024 Announcement CBIH: Unleashing the Potential of Cannabis for Tomorrow's Medicine
01 Jul 2024 Announcement Cyrus Taraporevala Elected to Pfizer’s Board of Directors
28 Jun 2024 CNBC Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline
28 Jun 2024 CNBC Rural retailer Tractor Supply eliminates DEI roles, Pride support and carbon emissions goals
27 Jun 2024 Announcement Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
26 Jun 2024 CNBC Biden administration to lower costs for 64 drugs through inflation penalties on drugmakers
26 Jun 2024 Announcement Pfizer Declares Third-Quarter 2024 Dividend
18 Jun 2024 Announcement Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
17 Jun 2024 CNBC FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia, serious infections
14 Jun 2024 Announcement ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
12 Jun 2024 Announcement Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
10 Jun 2024 CNBC Moderna's combination Covid, flu vaccine is more effective than existing shots in late-stage trial
07 Jun 2024 CNBC FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
05 Jun 2024 Announcement Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
03 Jun 2024 Announcement Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
01 Jun 2024 Announcement Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)
01 Jun 2024 Announcement Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
31 May 2024 Announcement Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
31 May 2024 CNBC Pfizer's drug for advanced lung cancer shows promising long-term trial results
31 May 2024 CNBC FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product
24 May 2024 CNBC Here's how U.S. health officials are responding to bird flu in humans after second case
16 May 2024 Announcement Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
13 May 2024 Announcement Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
06 May 2024 Announcement Pfizer Announces New Chief Strategy and Innovation Officer
01 May 2024 Announcement Pfizer Reports First-Quarter 2024 Results
29 Apr 2024 Announcement TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
29 Apr 2024 Announcement FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
29 Apr 2024 Announcement Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
Show more
TTM Dividend Yield 5.40%
5Y Average Dividend Yield 3.89%
Expected Next Dividend Payment Mar 2025
Ex Date Announcement Date Payment Date Details
26 Jul 2024 26 Jun 2024 03 Sep 2024 0.42 Cash
09 May 2024 24 Apr 2024 14 Jun 2024 0.42 Cash
25 Jan 2024 14 Dec 2023 01 Mar 2024 0.42 Cash
09 Nov 2023 04 Oct 2023 04 Dec 2023 0.41 Cash
27 Jul 2023 22 Jun 2023 05 Sep 2023 0.41 Cash
11 May 2023 26 Apr 2023 09 Jun 2023 0.41 Cash
26 Jan 2023 09 Dec 2022 03 Mar 2023 0.41 Cash
03 Nov 2022 22 Sep 2022 05 Dec 2022 0.4 Cash
28 Jul 2022 23 Jun 2022 06 Sep 2022 0.4 Cash
12 May 2022 28 Apr 2022 10 Jun 2022 0.4 Cash
27 Jan 2022 10 Dec 2021 04 Mar 2022 0.4 Cash
04 Nov 2021 23 Sep 2021 06 Dec 2021 0.39 Cash
29 Jul 2021 24 Jun 2021 07 Sep 2021 0.39 Cash
06 May 2021 22 Apr 2021 04 Jun 2021 0.39 Cash
28 Jan 2021 11 Dec 2020 05 Mar 2021 0.39 Cash
05 Nov 2020 24 Sep 2020 01 Dec 2020 0.38 Cash
30 Jul 2020 25 Jun 2020 01 Sep 2020 0.38 Cash
07 May 2020 23 Apr 2020 05 Jun 2020 0.38 Cash
30 Jan 2020 16 Dec 2019 06 Mar 2020 0.38 Cash
07 Nov 2019 24 Sep 2019 02 Dec 2019 0.36 Cash
01 Aug 2019 28 Jun 2019 03 Sep 2019 0.36 Cash
09 May 2019 26 Apr 2019 07 Jun 2019 0.36 Cash
31 Jan 2019 15 Dec 2018 01 Mar 2019 0.36 Cash
08 Nov 2018 28 Sep 2018 03 Dec 2018 0.34 Cash
02 Aug 2018 29 Jun 2018 04 Sep 2018 0.34 Cash
10 May 2018 26 Apr 2018 01 Jun 2018 0.34 Cash
01 Feb 2018 18 Dec 2017 01 Mar 2018 0.34 Cash
09 Nov 2017 27 Sep 2017 01 Dec 2017 0.32 Cash
02 Aug 2017 22 Jun 2017 01 Sep 2017 0.32 Cash
10 May 2017 27 Apr 2017 01 Jun 2017 0.32 Cash
01 Feb 2017 12 Dec 2016 01 Mar 2017 0.32 Cash
08 Nov 2016 22 Sep 2016 01 Dec 2016 0.3 Cash
03 Aug 2016 23 Jun 2016 01 Sep 2016 0.3 Cash
11 May 2016 28 Apr 2016 01 Jun 2016 0.3 Cash
03 Feb 2016 14 Dec 2015 02 Mar 2016 0.3 Cash
04 Nov 2015 25 Sep 2015 01 Dec 2015 0.28 Cash
05 Aug 2015 25 Jun 2015 02 Sep 2015 0.28 Cash
06 May 2015 23 Apr 2015 02 Jun 2015 0.28 Cash
04 Feb 2015 14 Dec 2014 03 Mar 2015 0.28 Cash
05 Nov 2014 23 Oct 2014 02 Dec 2014 0.26 Cash
30 Jul 2014 26 Jun 2014 03 Sep 2014 0.26 Cash
07 May 2014 24 Apr 2014 03 Jun 2014 0.26 Cash
05 Feb 2014 16 Dec 2013 04 Mar 2014 0.26 Cash
06 Nov 2013 24 Oct 2013 03 Dec 2013 0.24 Cash
31 Jul 2013 27 Jun 2013 04 Sep 2013 0.24 Cash
08 May 2013 25 Apr 2013 04 Jun 2013 0.24 Cash
30 Jan 2013 17 Dec 2012 05 Mar 2013 0.24 Cash
07 Nov 2012 25 Oct 2012 04 Dec 2012 0.22 Cash
01 Aug 2012 28 Jun 2012 05 Sep 2012 0.22 Cash
09 May 2012 26 Apr 2012 05 Jun 2012 0.22 Cash
01 Feb 2012 12 Dec 2011 06 Mar 2012 0.22 Cash
08 Nov 2011 27 Oct 2011 06 Dec 2011 0.2 Cash
03 Aug 2011 23 Jun 2011 06 Sep 2011 0.2 Cash
11 May 2011 28 Apr 2011 07 Jun 2011 0.2 Cash
02 Feb 2011 13 Dec 2010 01 Mar 2011 0.2 Cash
04 Nov 2010 28 Oct 2010 01 Dec 2010 0.18 Cash
04 Aug 2010 24 Jun 2010 01 Sep 2010 0.18 Cash
05 May 2010 22 Apr 2010 01 Jun 2010 0.18 Cash
03 Feb 2010 14 Dec 2009 02 Mar 2010 0.18 Cash
04 Nov 2009 22 Oct 2009 01 Dec 2009 0.16 Cash
05 Aug 2009 25 Jun 2009 02 Sep 2009 0.16 Cash
06 May 2009 23 Apr 2009 02 Jun 2009 0.16 Cash
04 Feb 2009 15 Dec 2008 03 Mar 2009 0.32 Cash
05 Nov 2008 23 Oct 2008 02 Dec 2008 0.32 Cash
06 Aug 2008 26 Jun 2008 03 Sep 2008 0.32 Cash
07 May 2008 24 Apr 2008 03 Jun 2008 0.32 Cash
06 Feb 2008 17 Dec 2007 04 Mar 2008 0.32 Cash
07 Nov 2007 25 Oct 2007 04 Dec 2007 0.29 Cash
08 Aug 2007 28 Jun 2007 05 Sep 2007 0.29 Cash
09 May 2007 26 Apr 2007 05 Jun 2007 0.29 Cash
07 Feb 2007 18 Dec 2006 06 Mar 2007 0.29 Cash
08 Nov 2006 26 Oct 2006 05 Dec 2006 0.24 Cash
09 Aug 2006 22 Jun 2006 05 Sep 2006 0.24 Cash
10 May 2006 27 Apr 2006 06 Jun 2006 0.24 Cash
08 Feb 2006 12 Dec 2005 07 Mar 2006 0.24 Cash
08 Nov 2005 27 Oct 2005 06 Dec 2005 0.19 Cash
10 Aug 2005 23 Jun 2005 06 Sep 2005 0.19 Cash
11 May 2005 28 Apr 2005 07 Jun 2005 0.19 Cash
09 Feb 2005 13 Dec 2004 08 Mar 2005 0.19 Cash
09 Nov 2004 28 Oct 2004 03 Dec 2004 0.17 Cash
11 Aug 2004 24 Jun 2004 03 Sep 2004 0.17 Cash
12 May 2004 22 Apr 2004 04 Jun 2004 0.17 Cash
11 Feb 2004 15 Dec 2003 05 Mar 2004 0.17 Cash
12 Nov 2003 23 Oct 2003 04 Dec 2003 0.15 Cash
13 Aug 2003 26 Jun 2003 04 Sep 2003 0.15 Cash
14 May 2003 24 Apr 2003 05 Jun 2003 0.15 Cash
15 Jan 2003 16 Dec 2002 14 Feb 2003 0.15 Cash
13 Nov 2002 24 Oct 2002 05 Dec 2002 0.13 Cash
14 Aug 2002 27 Jun 2002 05 Sep 2002 0.13 Cash
15 May 2002 25 Apr 2002 06 Jun 2002 0.13 Cash
13 Feb 2002 18 Dec 2001 07 Mar 2002 0.13 Cash
14 Nov 2001 25 Oct 2001 06 Dec 2001 0.11 Cash
15 Aug 2001 28 Jun 2001 06 Sep 2001 0.11 Cash
16 May 2001 26 Apr 2001 07 Jun 2001 0.11 Cash
14 Feb 2001 18 Dec 2000 08 Mar 2001 0.11 Cash
15 Nov 2000 26 Oct 2000 07 Dec 2000 0.09 Cash
16 Aug 2000 22 Jun 2000 07 Sep 2000 0.09 Cash
16 Aug 2000 01 Jun 2000 15 Sep 2000 0.09 Cash
09 May 2000 27 Apr 2000 08 Jun 2000 0.09 Cash
16 Feb 2000 13 Dec 1999 09 Mar 2000 0.09 Cash
09 Nov 1999 28 Oct 1999 09 Dec 1999 0.08 Cash
04 Aug 1999 24 Jun 1999 09 Sep 1999 0.08 Cash
05 May 1999 22 Apr 1999 10 Jun 1999 0.22 Cash
10 Feb 1999 14 Dec 1998 11 Mar 1999 0.22 Cash
04 Nov 1998 22 Oct 1998 10 Dec 1998 0.19 Cash
05 Aug 1998 25 Jun 1998 10 Sep 1998 0.19 Cash
06 May 1998 23 Apr 1998 11 Jun 1998 0.19 Cash
04 Feb 1998 22 Jan 1998 12 Mar 1998 0.19 Cash
05 Nov 1997 23 Oct 1997 11 Dec 1997 0.17 Cash
30 Jul 1997 26 Jun 1997 11 Sep 1997 0.17 Cash
07 May 1997 24 Apr 1997 12 Jun 1997 0.34 Cash
05 Feb 1997 23 Jan 1997 13 Mar 1997 0.34 Cash
06 Nov 1996 24 Oct 1996 12 Dec 1996 0.3 Cash
31 Jul 1996 27 Jun 1996 12 Sep 1996 0.3 Cash
08 May 1996 25 Apr 1996 13 Jun 1996 0.3 Cash
07 Feb 1996 25 Jan 1996 14 Mar 1996 0.3 Cash
08 Nov 1995 26 Oct 1995 21 Dec 1995 0.26 Cash
02 Aug 1995 22 Jun 1995 21 Sep 1995 0.26 Cash
08 May 1995 27 Apr 1995 15 Jun 1995 0.52 Cash
06 Feb 1995 26 Jan 1995 16 Mar 1995 0.52 Cash
04 Nov 1994 27 Oct 1994 15 Dec 1994 0.47 Cash
01 Aug 1994 23 Jun 1994 15 Sep 1994 0.47 Cash
09 May 1994 28 Apr 1994 16 Jun 1994 0.47 Cash
07 Feb 1994 27 Jan 1994 17 Mar 1994 0.47 Cash
05 Nov 1993 28 Oct 1993 16 Dec 1993 0.42 Cash
02 Aug 1993 25 Jun 1993 16 Sep 1993 0.42 Cash
10 May 1993 22 Apr 1993 17 Jun 1993 0.42 Cash
08 Feb 1993 28 Jan 1993 18 Mar 1993 0.42 Cash
16 Nov 1992 22 Oct 1992 17 Dec 1992 0.37 Cash
03 Aug 1992 25 Jun 1992 17 Sep 1992 0.37 Cash
11 May 1992 23 Apr 1992 18 Jun 1992 0.37 Cash
03 Feb 1992 23 Jan 1992 19 Mar 1992 0.37 Cash
08 Nov 1991 24 Oct 1991 19 Dec 1991 0.33 Cash
01 Aug 1991 27 Jun 1991 19 Sep 1991 0.33 Cash
13 May 1991 25 Apr 1991 20 Jun 1991 0.33 Cash
22 Feb 1991 24 Jan 1991 21 Mar 1991 0.66 Cash
09 Nov 1990 25 Oct 1990 20 Dec 1990 0.6 Cash
06 Aug 1990 28 Jun 1990 20 Sep 1990 0.6 Cash
14 May 1990 26 Apr 1990 21 Jun 1990 0.6 Cash
05 Feb 1990 25 Jan 1990 22 Mar 1990 0.6 Cash
13 Nov 1989 26 Oct 1989 21 Dec 1989 0.55 Cash
24 Jul 1989 22 Jun 1989 21 Sep 1989 0.55 Cash
15 May 1989 27 Apr 1989 21 Jun 1989 0.55 Cash
23 Jan 1989 19 Dec 1988 22 Mar 1989 0.55 Cash
15 Nov 1988 27 Oct 1988 20 Dec 1988 0.5 Cash
25 Jul 1988 23 Jun 1988 20 Sep 1988 0.5 Cash
16 May 1988 28 Apr 1988 20 Jun 1988 0.5 Cash
12 Feb 1988 28 Jan 1988 21 Mar 1988 0.5 Cash
16 Nov 1987 22 Oct 1987 21 Dec 1987 0.45 Cash
27 Jul 1987 25 Jun 1987 21 Sep 1987 0.45 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2024 1.26 3 4.10
2023 1.64 4 5.70
2022 1.60 4 3.12
2021 1.56 4 2.64
2020 1.52 4 4.13
2019 1.44 4 3.87
2018 1.36 4 3.28
2017 1.28 4 3.73
2016 1.20 4 3.89
2015 1.12 4 3.66
2014 1.04 4 3.52
2013 0.960 4 3.30
2012 0.880 4 3.70
2011 0.800 4 3.90
2010 0.720 4 4.33
2009 0.800 4 4.64
2008 1.28 4 7.62
2007 1.16 4 5.38
2006 0.960 4 3.91
2005 0.760 4 3.44
2004 0.680 4 2.67
2003 0.600 4 1.79
2002 0.520 4 1.79
2001 0.440 4 1.16
2000 0.450 5 1.03
1999 0.600 4 1.95
1998 0.760 4 1.92
1997 1.02 4 4.33
1996 1.20 4 9.14
1995 1.56 4 15.66
1994 1.88 4 30.78
1993 1.68 4 30.80
1992 1.48 4 25.82
1991 1.65 4 24.84
1990 2.40 4 75.18
1989 2.20 4 80.07
1988 2.00 4 87.23
1987 0.900 2 48.83
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria